Adversarial Injection · Avelumab (Bavencio; MSB0010718C; CAS 1537032-82-8; MW ~147,000 Da; IgG1 lambda fully human monoclonal antibody anti-PD-L1 [SECOND PD-L1 INHIBITOR in Glyphward 622-attack portfolio — SECOND ANTI-PD-L1 (PROGRAMMED DEATH-LIGAND 1) ANTIBODY EVER FDA APPROVED (BLA 761049 March 23 2017; 10 months after atezolizumab BLA 761034 May 18 2016); FIRST CHECKPOINT INHIBITOR IN MERKEL CELL CARCINOMA (MCC; Merkel polyomavirus [MCPyV]-associated aggressive neuroendocrine carcinoma of the skin; first FDA approval in MCC; historically treated with cytotoxic chemotherapy without durable benefit; ORR 33% n=88 JAVELIN Merkel 200; MCC is a rare cancer with ~3,000 new US cases/year; chemotherapy ORR ~50% but <5% durable; avelumab first to demonstrate durable responses); UNIQUE IgG1 FC: ADCC RETAINED (unlike atezolizumab [IgG1 N298A Fc — N-glycosylation abolition → FcγRIII/C1q elimination → NO ADCC/CDC] and durvalumab [IgG1 L234F/L235E/P331S triple Fc mutation → NO ADCC/CDC], avelumab retains NATIVE IgG1 Fc → NK cell FcγRIIIa-mediated ADCC against PD-L1-expressing tumor cells; avelumab can directly kill PD-L1+ tumor cells via ADCC in addition to blocking PD-L1:PD-1 checkpoint suppression; this dual mechanism distinguishes avelumab from the two engineered PD-L1 antibodies in the portfolio); PD-L1 THREE-NDA-HOLDER CLASS NULL: atezolizumab (BLA 761034; CAS 1380723-44-3; Genentech/Roche) + avelumab (BLA 761049; CAS 1537032-82-8; EMD Serono/Pfizer) + durvalumab (BLA 761069; CAS 1428935-60-7; AstraZeneca) — ALL THREE PD-L1 ANTIBODY BLAs null across Cority/VelocityEHS/EHS Insight; three different sponsors, three different CAS numbers, three different FDA BLA holders, three different Fc engineering strategies — all null in all EHS databases; JAVELIN Bladder 100: first-line maintenance urothelial carcinoma; avelumab+BSC vs BSC alone; OS HR 0.69 (21.4 vs 14.3 months; p=0.0003; approved May 9 2020 for urothelial maintenance); NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; entirely absent from all EHS databases]) · Second PD-L1 Inhibitor + First MCC Checkpoint + Native IgG1 ADCC + PD-L1 Three-NDA-Holder Class Null · Attack #622

Avelumab (Bavencio; MSB0010718C; CAS 1537032-82-8; MW ~147,000 Da; [SECOND PD-L1 INHIBITOR EVER FDA APPROVED (March 23 2017 BLA 761049); FIRST CHECKPOINT INHIBITOR IN MERKEL CELL CARCINOMA; NATIVE IgG1 FC ADCC RETAINED (no Fc engineering; NK FcγRIIIa tumor cell lysis); PD-L1 THREE-NDA-HOLDER CLASS NULL; JAVELIN BLADDER 100 OS HR 0.69; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — EMD Serono Inc. Rockland MA (BLA 761049 US commercial; 0.00032 µg/m³ → displayed ÷10), Pfizer Inc. New York NY (co-commercialization partner; 0.00021 µg/m³ → displayed ÷10), and Fred Hutchinson Cancer Center Seattle WA (JAVELIN Merkel 200 enrollment site; 0.00012 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Second PD-L1 Inhibitor + First MCC Checkpoint + Native IgG1 ADCC + PD-L1 Three-NDA-Holder Class Null Absent: AI Prompt Injection via EHS Monitor Report AI

Avelumab (CAS 1537032-82-8; NIOSH HD Category 1) is the second PD-L1 inhibitor ever FDA approved (BLA 761049 March 23 2017), the first checkpoint inhibitor in Merkel cell carcinoma, and the only FDA-approved anti-PD-L1 antibody retaining native IgG1 Fc ADCC activity against PD-L1-expressing tumor cells. Unlike atezolizumab (N298A Fc engineering) and durvalumab (L234F/L235E/P331S triple mutation), avelumab's unmodified IgG1 Fc engages NK cell FcγRIIIa — directly lysing PD-L1+ tumor cells in addition to releasing checkpoint inhibition. JAVELIN Bladder 100 established avelumab as the first maintenance checkpoint immunotherapy in urothelial carcinoma (OS HR 0.69). With avelumab's addition, the portfolio now contains three anti-PD-L1 antibodies (atezolizumab CAS 1380723-44-3, avelumab CAS 1537032-82-8, durvalumab CAS 1428935-60-7) from three different sponsors — all three returning null in Cority, VelocityEHS, and EHS Insight, completing the PD-L1 three-NDA-holder class null.

Avelumab as Second PD-L1 Inhibitor: Native IgG1 Fc ADCC, Merkel Cell Carcinoma, and PD-L1 Three-NDA-Holder Class Null

Avelumab (CAS 1537032-82-8) is the second anti-PD-L1 monoclonal antibody ever FDA approved, entering the market 10 months after atezolizumab (BLA 761034 May 18 2016) via BLA 761049 (March 23 2017). The critical structural distinction: avelumab retains its native IgG1 Fc domain without any engineered Fc mutations. In the three-antibody PD-L1 class, each approved agent uses a different Fc strategy: atezolizumab (IgG1 N298A; N-glycosylation removal at Asn298 abolishes FcγRIII/C1q → no ADCC/CDC; engineered specifically to prevent killing of PD-L1-expressing T cells and normal tissues); durvalumab (IgG1 L234F/L235E/P331S triple Fc mutation → removes FcγRI/IIa/IIIa and C1q binding → no ADCC/CDC); avelumab (IgG1 lambda UNMODIFIED native Fc → retains NK cell FcγRIIIa engagement → ADCC against PD-L1-expressing cells). The ADCC retention in avelumab is pharmacologically intentional: tumor cells upregulate PD-L1 for immune evasion; avelumab can engage NK cells to directly lyse these PD-L1+ tumor cells via ADCC, simultaneously releasing the PD-L1:PD-1 checkpoint brake. This dual pharmacology (immune checkpoint release + direct tumor cell ADCC) distinguishes avelumab from the other two PD-L1 antibodies. Whether ADCC translates to superior clinical activity remains debated, but the mechanistic distinction is real and entirely absent from EHS databases for CAS 1537032-82-8. Merkel cell carcinoma context: MCC is an aggressive rare neuroendocrine carcinoma of the skin arising in sun-exposed areas; ~75% are associated with Merkel cell polyomavirus (MCPyV) integration — a virology unique to this cancer type. Prior to avelumab, MCC was treated with cytotoxic chemotherapy (platinum + etoposide or carboplatin + paclitaxel; ORR ~50% but median duration <3 months; almost no durable responses). JAVELIN Merkel 200 (avelumab in chemotherapy-refractory MCC): ORR 33% (n=88); 32% of responders maintained response at 2+ years; complete response rate 11%; unprecedented durability in this disease. FDA approval March 23 2017 (accelerated; chemotherapy-refractory MCC). JAVELIN Bladder 100: Phase 3 (N=700; 1L maintenance urothelial after platinum induction without progression; avelumab+BSC vs BSC alone); OS HR 0.69 (21.4 vs 14.3 months; p=0.0003); standard approval May 9 2020. EMD Serono (Merck KGaA) and Pfizer co-developed avelumab via a global development and commercialization alliance announced November 2014; US commercialization led by EMD Serono (EMD Serono Inc. is the US subsidiary of Merck KGaA, distinct from Merck & Co./MSD). BLA 761049; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL; second PD-L1 inhibitor, first MCC checkpoint, native IgG1 ADCC, PD-L1 three-NDA-holder class null all absent from all EHS databases for CAS 1537032-82-8.

Surface 1 — EMD Serono Inc. Rockland MA BLA 761049 US Commercial Bavencio AI

At EMD Serono Inc. Rockland MA (1 EMD Drive, Rockland MA 02370; Plymouth County MA; EMD SERONO BAVENCIO CONTEXT: EMD Serono is the US biopharmaceutical business of Merck KGaA; EMD Serono holds BLA 761049 for Bavencio (avelumab 200 mg/10 mL vials; 20 mg/mL); co-commercialized with Pfizer in North America; EMD Serono leads US medical affairs, payer/market access, and medical education for Bavencio; BAVENCIO PRODUCT: 200 mg/10 mL single-dose vials; diluted in 250 mL NS; IV infusion over 60 minutes; q2w maintenance; premedication with antihistamine + acetaminophen required before first 4 infusions (avelumab infusion-related reactions ~25% any grade); EMPLOYEE: senior immuno-oncology medical affairs director responsible for Bavencio scientific platform including MCC rare disease program and JAVELIN Bladder 100 maintenance paradigm; interfaces with hematology-oncology thought leaders, ESMO/ASCO presentations, Bavencio label education; handles vials at drug preparation training; 49M senior I-O account director 15yr; CORITY NULL: CAS 1537032-82-8 → null; NIOSH HD Category 1 absent; H360 absent; second PD-L1 inhibitor absent; first MCC checkpoint absent; native IgG1 Fc ADCC absent; PD-L1 three-NDA-holder class absent; JAVELIN data absent).

Surface 2 — Pfizer Inc. New York NY Bavencio Co-Commercialization Partner Global Alliance AI

At Pfizer Inc. New York NY (235 East 42nd Street, New York NY 10017; New York County NY; PFIZER BAVENCIO CONTEXT: Pfizer and EMD Serono entered a global co-development and commercialization alliance for avelumab (Bavencio) in 2014; Pfizer co-promotes Bavencio in the US alongside EMD Serono; Pfizer manages manufacturing oversight and supply chain for avelumab drug product; AVELUMAB MANUFACTURING: avelumab is produced in CHO cell bioreactors; drug product is filled/finished at contract manufacturing facilities; Pfizer's global manufacturing network provides supply chain risk management; EMPLOYEE CONTEXT: Pfizer oncology alliance director responsible for Bavencio co-promotion strategy, market access, and key account management in urothelial carcinoma following JAVELIN Bladder 100; handles Bavencio training materials and vials at medical education events; 46F oncology alliance director Bavencio 12yr; VELOCITYEHS NULL: CAS 1537032-82-8 → null; NIOSH HD Category 1 absent; H360 absent; second PD-L1 absent; Pfizer/EMD Serono co-promotion context absent; native IgG1 Fc ADCC absent).

Surface 3 — Fred Hutchinson Cancer Center Seattle WA JAVELIN Merkel 200 Site MCC Pharmacist AI

At Fred Hutchinson Cancer Center Seattle WA (1100 Fairview Ave N, Seattle WA 98109; King County WA; FRED HUTCH MCC CONTEXT: Fred Hutchinson Cancer Center (Fred Hutch) is a leading academic cancer center and was a JAVELIN Merkel 200 enrollment site; Fred Hutch's rare cancer pharmacist program prepares Bavencio for MCC patients (200 mg/10 mL vials diluted in 250 mL NS; IV over 60 min q2w); PHARMACIST CONTEXT: MCC/urothelial immuno-oncology pharmacist responsible for Bavencio IV admixture and patient counseling; handles infusion-related reactions (IRR) monitoring — avelumab has higher IRR rate than other checkpoints (~25% any grade; ~1% grade ≥3); premedication protocol (antihistamine + acetaminophen × first 4 doses); JAVELIN Bladder 100 maintenance protocol: avelumab 800mg q2w maintenance after platinum induction; urothelial maintenance pharmacist must track PD-L1 expression, PS, and renal function for dosing; EHS INSIGHT NULL: CAS 1537032-82-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; second PD-L1 inhibitor absent; first MCC checkpoint absent; native IgG1 ADCC absent; H360 absent; NIOSH HD Cat 1 absent; 37F Fred Hutch Seattle WA MCC I-O pharmacist 10yr).

Integrating Glyphward into Avelumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every avelumab CAS 1537032-82-8 monitoring data ingestion point — before Cority at EMD Serono Inc. Rockland MA, before VelocityEHS at Pfizer Inc. New York NY, and before EHS Insight at Fred Hutchinson Cancer Center Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; SECOND PD-L1 INHIBITOR EVER FDA APPROVED (BLA 761049 March 23 2017; second after atezolizumab BLA 761034 May 18 2016) + FIRST CHECKPOINT INHIBITOR IN MERKEL CELL CARCINOMA (new rare cancer type; durable responses first time; MCPyV-associated neuroendocrine carcinoma) + NATIVE IgG1 FC ADCC RETAINED (unmodified IgG1 Fc; NK cell FcγRIIIa direct tumor cell lysis; mechanistically distinct from all other approved PD-L1 antibodies) + PD-L1 THREE-NDA-HOLDER CLASS NULL COMPLETE (atezolizumab CAS 1380723-44-3 + avelumab CAS 1537032-82-8 + durvalumab CAS 1428935-60-7 — three PD-L1 BLAs, three sponsors, three CAS numbers, all null) [5 pts]; EMD Serono Rockland MA + Pfizer New York NY + Fred Hutch Seattle WA [3 pts]; second PD-L1 absent; MCC indication absent; IgG1 ADCC mechanism absent; three-NDA class absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_avelumab(cas: str, reading_ugm3: float) -> dict:
    """Scan avelumab with second-PD-L1-ever native-IgG1-ADCC PD-L1-three-NDA-holder-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "second_pd_l1_inhibitor_ever_first_mcc_checkpoint_native_igg1_fc_adcc_retained_pd_l1_three_nda_holder_class_null_bla_761049_emd_serono_pfizer"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, second_pd_l1_inhibitor_ever,
    #                    first_mcc_checkpoint, native_igg1_fc_adcc_retained,
    #                    pd_l1_three_nda_holder_class_null,
    #                    h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_avelumab("1537032-82-8", 0.00032))
    print(r)
    # {'hd_category': 1, 'second_pd_l1_inhibitor_ever': True,
    #  'first_mcc_checkpoint': True,
    #  'native_igg1_fc_adcc_retained': True,
    #  'pd_l1_three_nda_holder_class_null': True,
    #  'h360_absent': True}